| [November 22, 2016] |
 |
NeuroMetrix Announces That Quell Will Be Featured on The Henry Ford Innovation Nation
NeuroMetrix, Inc. (Nasdaq: NURO,NUROW) announced today that its Quell®
Wearable Pain Relief Technology™ will be featured on the November
26th episode of The Henry Ford (News - Alert) Innovation Nation which
airs on the CBS network on Saturday mornings as part of its "CBS Dream
Team" lineup.
Innovation Nation correspondent Alie Ward visited the NeuroMetrix
offices in Waltham, MA in June to interview NeuroMetrix Founder & CEO,
Shai Gozani, M.D., Ph.D. "We're proud of Quell and the impact it's
having on chronic pain sufferers' lives. We appreciate the Innovation
Nation team's interest in learning more about the Quell technology and
sharing our story with its viewers," said Dr. Gozani.
Check your local listings for The Henry Ford Innovation Nation
this Saturday, November 26th on CBS.
About Quell
Quell is designed for millions of people
suffering from chronic pain. The advanced wearable device is lightweight
and can be worn during the day while active, and at night while
sleeping. It has been cleared by the FDA for treatment of chronic pain
without a prescription. In a recent study, 81% of Quell users reported
an improvement in their chronic pain. Quell users cn start, stop, and
adjust therapy discreetly via the optional Quell Relief app. Quell also
offers advanced sleep tracking that provides feedback on eight
dimensions of sleep including sleep duration, quality, body position,
time out of bed, and repetitive leg movements throughout the night.
Quell was the winner of the 2016 SXSW (News - Alert) (South by Southwest) Innovation
Award for Best Wearable Technology. Quell is available at select
healthcare professionals and retailers. Visit QuellRelief.com for
more information.
About NeuroMetrix
NeuroMetrix is a commercial stage,
innovation driven healthcare company combining bioelectrical and digital
medicine to address chronic health conditions including chronic pain,
sleep disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain. Quell is
integrated into a digital health platform that helps patients optimize
their therapy and decrease the impact of chronic pain on their quality
of life. The company also markets DPNCheck®, a rapid
point-of-care test for diabetic neuropathy, which is the most common
long-term complication of Type 2 diabetes. The company maintains an
active research effort and has several pipeline programs, including a
therapeutic device for restless leg syndrome. The company is located
in Waltham, Massachusetts and was founded as a spinoff from
the Harvard-MIT (News - Alert) Division of Health Sciences and Technology in 1996. For
more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005715/en/
[ Back To TMCnet.com's Homepage ]
|
